Current Research Studies

Cancer – AAML1421: Phase 1/2 Study of CPX-351 Alone Followed By Fludarabine, Cytarabine and G-CSF for Children with Relapsed Acute Myeloid Leukemia

Condition or Therapy:

Acute Myeloid Leukemia


Cancer and Blood Disorders
Study Number: AAML1421

What is the goal of this study?

This study is looking at how well a patient with relapsed or refractory Acute Myeloid Leukemia (AML) responds when given liposome-encapsulated daunorubicin-cytarabine with fludarabine phosphate, cytarabine and filgrastim.

Who can join the study?

This study may be a good fit for children and young adults who:

  • are 1 to 21 years old, and
  • have had relapsed or refractory AML.

What will happen if my child takes part in this study?

You can read more about this study on

Who can I contact for more information?

To learn more, call 206-987-2106 or email the study coordinator.

Study Location(s):

Seattle Children's Main Hospital Campus

Principal Investigator:

Dr. Douglas Hawkins